Hims & Hers Health (HIMS)
(Delayed Data from NYSE)
$50.89 USD
-3.07 (-5.69%)
Updated Sep 16, 2025 03:59 PM ET
After-Market: $50.35 -0.54 (-1.06%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Hims & Hers Health, Inc. has a PEG ratio of 4.04 compared to the Medical Info Systems industry's PEG ratio of 3.35.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
HIMS 50.89 -3.07(-5.69%)
Will HIMS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for HIMS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HIMS
Hims & Hers Expands AI and Technology Focus to Advance Digital Care
Company News for Sep 16, 2025
HIMS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Hims & Hers Health, Inc. (HIMS) Stock Sinks As Market Gains: Here's Why
OMCL or HIMS: Which Is the Better Value Stock Right Now?
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
Other News for HIMS
Hims & Hers Stock (HIMS) Slumps as FDA Slams Its ‘False’ Weight Loss Drug Products
Trump announces $15B libel suit against New York Times: Morning Buzz
Trump announces $15B libel suit against New York Times: Morning Buzz
HIMS Stock Dips After FDA Warning on Marketing Claims
Trump announces $15 libel suit against New York Times: Morning Buzz